Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ulthera, Inc | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to demonstrate superiority of treatment with the Ulthera System compared to untreated control for the improvement of skin laxity of the lower face, submental area and neck and to demonstrate the safety of treatment with the Ulthera System for the improvement of skin laxity of the lower face, submental area and neck.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment With Ulthera System | Experimental | Participants randomized to receive a single treatment with Ulthera system to lower face, submentum and neck on Day 1. |
|
| Control/Delayed treatment With Ulthera System | Other | Participants will remain untreated until Day 90 and then receive a single treatment with Ulthera system to lower face, submentum and neck. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ulthera System | Device | Participants will receive treatment with the Ulthera system which consists of three primary components: the control unit, handpiece and interchangeable transducers. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants With at Least "Improved" in Lower Face, Submental and Neck Skin Laxity on Global Aesthetic Improvement Scale as Determined by the Blinded Live Evaluator (eGAIS) at Day 90 Compared to Baseline Photographs | Blinded live evaluator will use eGAIS to evaluate global aesthetic improvement in the facial appearance of participants. The GAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome. | Day 90 |
| Measure | Description | Time Frame |
|---|---|---|
| Three Independent, Blinded Raters GAIS (rGAIS) Score in Lower Face, Submental and Neck Skin Laxity at Day 90 Compared to Baseline Photographs | Three independent, blinded raters will use rGAIS to evaluate global aesthetic improvement in the facial appearance of participants. The GAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Scarring in area(s) to be treated.
Any active implants.
Any metallic implants in area(s) to be treated.
Any open wounds or lesions, including active herpes simplex, in the area(s) to be treated.
Presence of an active systemic or local skin disease, including active, cystic, or severe inflammatory acne in the area(s) to be treated.
History of keloid formation or hypertrophic scarring.
History of the following cosmetic treatments in area(s) to be treated:
Had prior surgery in the lower-facial area and/or neck/submentum or has a permanent implant or graft in the lower-facial area that could interfere with effectiveness assessments.
Has undergone oral surgery in the past 30 days.
Participants who have used isotretinoin or other retinoid medications within 6 months prior to enrollment or have applied topical retinoid-containing medications on the face or neck area within 2 weeks prior to enrollment or planning such treatments during the study period.
Marked facial asymmetry, deep dermal scarring, or thick sebaceous skin in the full face.
Severe solar elastosis.
Facial nerve palsy or history of facial nerve palsy.
Tattoos in the area(s) to be treated (excluding microblading eyebrow).
Current smoker or history of smoking in the last 12 months.
Current daily user of any nicotine-containing products
Is a female of childbearing potential1 and not using medically effective birth control 2 or is pregnant, lactating, or planning to become pregnant during the clinical investigation.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Public Disclosure Manager Merz Aesthetics | Contact | +1 984-301-3095 | Aesthetic.Trials@merz.com |
| Name | Affiliation | Role |
|---|---|---|
| Merz Medical Expert | Merz North America, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Merz Investigative Site | Recruiting | Beijing | Beijing Municipality | 100034 | China | |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003483 | Cutis Laxa |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003240 | Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 90 |
| Treating Investigator's GAIS (iGAIS) Score in Lower Face, Submental and Neck Skin Laxity at Day 90 Compared to Baseline Photographs | Treating investigators will use the iGAIS to assess overall aesthetic improvement of the lower face, submentum, and neck. The GAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome. This outcome measure is prespecified for the Treatment Group only. | Day 90 |
| Participant's GAIS (pGAIS) Scores in Lower Face, Submental Skin and Neck Laxity at Day 90 Compared to Baseline Photographs | Participants will self-report using the pGAIS to assess overall aesthetic improvement of the lower face, submentum, and neck. The pGAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome. This outcome measure is prespecified for the Treatment Group only. | Day 90 |
| Merz Investigative Site |
| Recruiting |
| Beijing |
| Beijing Municipality |
| 100730 |
| China |
| Merz Investigative Site | Recruiting | Guangzhou | Guangdong | 510317 | China |
| Merz Investigative Site | Recruiting | Nanjing | Jiangsu | 210003 | China |
| Merz Investigative Site | Recruiting | Xi'an | Shaanxi | 710004 | China |
| Merz Investigative Site | Recruiting | Shanghai | Shanghai Municipality | 200040 | China |
| Merz Investigative Site | Recruiting | Shanghai | Shanghai Municipality | 200443 | China |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |